<DOC>
	<DOC>NCT00579020</DOC>
	<brief_summary>The purpose of the study is to determine whether Moxidex ophthalmic solution is safe and effective in treating marginal corneal infiltrates.</brief_summary>
	<brief_title>A Phase II Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>Diagnosis of marginal corneal infiltrates of size equal to or less than 1.5mm in diameter, with mild, moderate or severe bulbar conjunctival injection in at least one eye. Other protocoldefined inclusion criteria may apply. Age related. Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>cornea</keyword>
	<keyword>inflammation</keyword>
	<keyword>blepharitis</keyword>
	<keyword>lid infection</keyword>
</DOC>